Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7084835 | 0.71 | AKR1C3 (0.56) | AKR1C3ALDH1A1AKR1C1MEN1KMT2A | |
| Fluoride SCHEMBL28793265 | 0.70 | KMT2A (0.47) | AKR1C3ALDH1A1AKR1C1MEN1KMT2A | |
| SCHEMBL30885716 | 0.69 | KMT2A (0.50) | AKR1C3ALDH1A1AKR1C1MEN1KMT2A | |
| SCHEMBL8117456 | 0.69 | KMT2A (0.50) | AKR1C3ALDH1A1AKR1C1MEN1KMT2A | |
| SCHEMBL6241042 | 0.69 | KMT2A (0.50) | AKR1C3ALDH1A1AKR1C1MEN1KMT2A | |
| SCHEMBL2694482 | 0.68 | MEN1 (0.76) | AKR1C3ALDH1A1AKR1C1MEN1KMT2A | |
| SCHEMBL28019824 | 0.68 | LIPE (0.50) | AKR1C3ALDH1A1AKR1C1SMN1; SMN2NAMPT | |
| SCHEMBL31680887 | 0.68 | SMN1; SMN2 (0.56) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL31535075 | 0.68 | POLB (0.57) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL1266336 | 0.67 | ESR1 (0.49) | AKR1C3ALDH1A1AKR1C1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | AKR1C3 593/4885ALDH1A1 212/4885AKR1C1 454/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | AKR1C3 407/4885ALDH1A1 118/4885AKR1C1 245/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | AKR1C3 593/4885ALDH1A1 212/4885AKR1C1 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.